Anti-tumor activity of folate receptor targeting docetaxel-loaded membrane-modified liposomes.
- Author:
Xiang LI
1
;
Jing ZHANG
;
Dong-Kai WANG
;
Wei-San PAN
Author Information
1. National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
administration & dosage;
pharmacology;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Cyanoacrylates;
chemistry;
Drug Carriers;
Female;
Folate Receptors, GPI-Anchored;
chemistry;
Humans;
Inhibitory Concentration 50;
Liposomes;
chemistry;
Lung Neoplasms;
pathology;
MCF-7 Cells;
Mice;
Neoplasm Transplantation;
Particle Size;
Polyethylene Glycols;
chemistry;
Rabbits;
Random Allocation;
Sarcoma 180;
pathology;
Taxoids;
administration & dosage;
pharmacology;
Tumor Burden;
drug effects
- From:
Acta Pharmaceutica Sinica
2013;48(7):1142-1147
- CountryChina
- Language:Chinese
-
Abstract:
The anti-tumor activity of folate receptor targeting docetaxel-loaded membrane-modified liposomes (FA-PDCT-L) was investigated in vitro and in vivo. FA-PDCT-L was prepared by organic solvent injection method. Transmission electron microscope, dynamic light scattering and electrophoretic light scattering were employed to study the physicochemical parameters of FA-PDCT-L. The inhibitory effects of docetaxel injection (DCT-I), non-modified DCT liposomes (DCT-L) and FA-PDCT-L on the growth of MCF-7 and A-549 cells at different incubation times were detected by CCK-8 assay; and the hemolytic test was employed in vitro. Tumor mice were randomized into 4 groups: DCT-I, DCT-L, FA-PDCT-L and control group (normal saline), and given drugs at 10 mg x kg(-1) x d(-1) through tail vein. The tumor volume, mice weight, inhibition rate of tumor and life span were measured at the end of experiments. The IC50 of the FA-PDCT-L for MCF-7 and A549 cell lines were significantly lower than that of DCT-I and DCT-L, without hemolysis reaction observed. Compared with control group, the weights of tumor in DCT-I, DCT-L and FA-PDCT-L were decreased, especially for FA-PDCT-L, with inhibitory rates at 79.03 % (P < 0.05). The life span and median survival time of FA-PDCT-L treated mice were significantly higher than that of DCT-I and DCT-L. In conclusion, FA-PDCT-L shows a good anti-tumor activity, indicating that it is potential carriers for DCT in the treatment of tumor.
